Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
| Revenue (TTM) | $682.20M |
| Gross Profit (TTM) | $571.55M |
| EBITDA | $-62.64M |
| Operating Margin | -16.20% |
| Return on Equity | -319.80% |
| Return on Assets | -7.88% |
| Revenue/Share (TTM) | $15.54 |
| Book Value | $2.11 |
| Price-to-Book | 31.97 |
| Price-to-Sales (TTM) | 4.96 |
| EV/Revenue | 4.529 |
| EV/EBITDA | -3.23 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 63.90% |
| Shares Outstanding | $49.31M |
| Float | $36.79M |
| % Insiders | 2.66% |
| % Institutions | 97.82% |
Volatility is currently contracting
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:
Tarsus Pharmaceuticals NASDAQ: TARS reported record third-quarter sales for XDEMVY and raised its full-year revenue outlook, citing increased patient demand, deeper prescribing activity among eye care professionals and a growing contribution from retreatment prescriptions.
Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales since launch Appointed Neera Clase as Chief Commercial Officer Management to host conference call today, November 3, 2026, at 1:30 p.m. PT / 4:30 p.m.
The average of price targets set by Wall Street analysts indicates a potential upside of 30.8% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update.
Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tarsus Pharmaceuticals is transitioning from a single-product launch story to a cash-generating eye care platform, with XDEMVY now funding the business. TARS raised XDEMVY 2026 net sales guidance to $685–$705 million, with gross margins in the low 90s and positive operating cash flow of $37 million in H1 2026. Recent retina acquisitions (iRenix, and Alkeus) are milestone-heavy, minimizing upfront risk and leveraging a targeted commercial infrastructure for future launches.
IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual Meeting, taking place Sept. 30–Oct. 3 in Anaheim, California.
Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved therapy Strengthens Tarsus' differentiated pipeline and leadership in eye care IRVINE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it has completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a privately held retinal disease-focused biotechnology company.
Daily treatment with oral gildeuretinol met the primary endpoint and resulted in a statistically significant reduction in the growth rate of retinal atrophic lesions compared to untreated group. Gildeuretinol was well tolerated with no patient-reported events of dark adaptation delays or night blindness.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TARS and any ticker you trade — then tracks every position and per-strategy win rate.
